Human Immunodeficiency Virus
Conditions
Keywords
Broadly Neutralizing Antibody, 3BNC117-LS, First in Human, Dose Escalation
Brief summary
The proposed study is a phase 1 study of the mAb 3BNC117-LS administered intravenously in HIV uninfected individuals and HIV-infected individuals, and subcutaneously in HIV-uninfected individuals.The objectives of the study are to evaluate the safety, tolerability and pharmacokinetics of a single administration of 3BNC117-LS.
Detailed description
The proposed study is a Phase 1, open label, dose escalation cohort study of 3BNC117-LS administered intravenously in HIV-uninfected and HIV-1 infected participants. This study consists of two parts. In part A, study participants will be enrolled in an open label manner to receive a single intravenous infusion of 3BNC117-LS at one of three increasing dose levels (3 mg/kg, 10 mg/kg and 30 mg/kg). Participants in Part B will also receive a single administration of 3BNC117-LS, however, the product administered in Part B of the study derives from a new manufacturing lot. The manufacturing lot used in Part A had incomplete glycosylation of the 3BNC117-LS light chain, which has been corrected in the new lot. Participants in Part B will receive 3BNC117-LS intravenously at 30 mg/kg in an open label manner (HIV-uninfected and HIV-infected) or will be randomized to receive a subcutaneous injection of 3BNC117-LS or placebo in a double-blinded fashion (HIV-uninfected only). Part A has already been enrolled with 21 participants. Part B has a planned enrollment of 22 participants. Part A * Group 1A (n=3-6) - HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 3 mg/kg. * Group 1B (n=3-6) - HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg. * Group 1C (n=3-6) - HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg. * Group 2B (n=6) - HIV-infected individuals on ART with HIV-1 plasma RNA levels \< 20 copies/ml or off ART for at least 8 weeks with HIV-1 plasma RNA levels \< 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 10 mg/kg. * Group 2C (n=6) - HIV-infected individuals on ART with HIV-1 plasma RNA levels \< 20 copies/ml, or off ART for at least 8 weeks with HIV-1 plasma RNA levels \< 100,000 copies/ml, will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg. Part B * Group 1D (n=3) - HIV-uninfected individuals will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg. * Group 2D (n=3) - HIV-infected individuals on ART with HIV-1 plasma RNA levels \< 20 copies/ml will be administered one infusion of 3BNC117-LS dosed at 30 mg/kg. * Group 1E (n=8) - HIV-uninfected individuals will be administered a single 1 mL (approximately 150 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio. * Group 1F (n=8) - HIV-uninfected individuals will be administered a single 2 mL (approximately 300 mg) subcutaneous injection of 3BNC117-LS or placebo in a 3:1 ratio. Following 3BNC117-LS infusion, study participants will return for safety assessments at weeks 1, 2 and 4 following infusion, then bi-monthly or monthly until the end of study follow up. Serum samples for PK (pharmacokinetic) measurements will be collected before 3BNC117-LS infusion, at the end of the infusion, and at multiple time points during study follow up. Samples will also be collected for measurement of HIV-1 plasma RNA levels before 3BNC117-LS infusion (screen, pre-infusion and day 0) and at all follow up visits in Groups 2B and 2C. All participants will be followed for 48 weeks after 3BNC117-LS administration.
Interventions
DRUG3BNC117-LS
Intravenous infusion of 3BNC117-LS
DRUGPlacebo
Placebo
Sponsors
Rockefeller University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
Groups 1A-1F (HIV-uninfected): 1. Males and females, age 18 to 65 2. Amenable to HIV risk reduction counseling and agrees to maintain behavior consistent with low risk of HIV exposure. 3. If sexually active male or female, and participating in sexual activity that could lead to pregnancy, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) from 10 days prior to and until seven months after 3BNC117-LS infusion, and agrees to safer sex counseling at each visit. * Female study participants of reproductive potential are defined as pre-menopausal women who have not had a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy). Women are considered menopausal if they have not had a menses for at least 12 months and have a FSH of greater than 40 IU/L or if FSH testing is not available, they have had amenorrhea for 24 consecutive months. Groups 2B-2D (HIV-infected): 1. Males and females, age 18 to 65. 2. HIV-1 infection confirmed by two laboratory assays. 3. HIV-infected individuals off ART for at least 8 weeks with HIV-1 plasma RNA levels \< 100,000 copies/ml by standard assays (ART-naïve or off ART due to intolerance or by choice), or on ART with HIV-1 plasma RNA levels \< 20 copies/ml. HIV-1 RNA levels should be measured on 2 occasions, at least 1 week apart. At least one measurement must be performed within 49 days prior to enrollment (day 0). Group 2D will only enroll HIV-infected individuals on ART. 4. Current CD4+ T cell count \> 300 cells/μl. 5. If sexually active male or female, and participating in sexual activity that could lead to pregnancy or transmission of HIV, agrees to use two effective methods of contraception (i.e. condom with spermicide, diaphragm with spermicide, hormone-eluting IUD, hormone-based contraceptive with condom) from 10 days prior to and until seven months after 3BNC117-LS infusion, and agrees to safer sex counseling at each visit.
Exclusion criteria
Groups 1A-1F (HIV-uninfected): 1. Confirmed HIV-1 or HIV-2 infection. 2. History of immunodeficiency or autoimmune disease; use of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months. 3. Any clinically significant acute or chronic medical condition (such as autoimmune diseases) that in the opinion of the investigator would preclude participation. 4. Within the 12 months prior to enrollment, the participant has a history of sexually transmitted infection. 5. Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood. 6. Laboratory abnormalities in the parameters listed: * Absolute neutrophil count ≤ 1,500 cells/µL; * Hemoglobin ≤ 11 gm/dL if female; ≤ 12.5 gm/dL if male; * Platelet count ≤ 125,000 cells/µL; * Alanine transaminase (ALT) ≥ 1.25 x ULN; * Aspartate transaminase (AST) ≥ 1.25 x ULN; * Alkaline phosphatase ≥ 1.5 x ULN; * Total bilirubin \> 1 x ULN; * Estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2. 7. Pregnancy or lactation. 8. Any vaccination within 14 days prior to 3BNC117-LS infusion. 9. Receipt of any experimental HIV vaccine or monoclonal antibody therapy of any kind in the past. 10. History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions. 11. Individuals with known hypersensitivity to any constituent of the investigational product. 12. Receipt of another investigational product currently or within the past 12 weeks, or expected concurrent participation in another study in which investigational products will be administered. Groups 2B-2D (HIV-infected): 1. Have a history of AIDS-defining illness within 3 years prior to enrollment. 2. History of systemic corticosteroids, immunosuppressive anti-cancer, or other medications considered significant by the trial physician within the last 6 months. 3. Any clinically significant acute or chronic medical condition (such as autoimmune diseases), other than HIV infection, that in the opinion of the investigator would preclude participation. 4. Hepatitis B or C infection as indicated by the presence of Hepatitis B surface antigen (HBsAg) or hepatitis C virus RNA (HCV-RNA) in blood. 5. Laboratory abnormalities in the parameters listed below: * Absolute neutrophil count ≤ 1,000 cells/μl; * Hemoglobin ≤ 10 gm/dL; * Platelet count ≤ 100,000 cells/μl; * ALT ≥ 1.5 x ULN; * AST ≥ 1.5 x ULN; * Alkaline phosphatase ≥ 1.5 x ULN; * Total bilirubin \> 1 x ULN; * eGFR \< 60 mL/min/1.73m2. 6. Pregnancy or lactation. 7. Any vaccination within 14 days prior to 3BNC117-LS infusion. 8. Receipt of any experimental HIV vaccine or monoclonal antibody therapy of any kind in the past. 9. History of severe reaction to a vaccine or drug infusion or history of severe allergic reactions. 10. Individuals with known hypersensitivity to any constituent of the investigational product. 11. Receipt of another investigational product currently or within the past 12 weeks, or expected concurrent participation in another study in which investigational products will be administered.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Participants Who Experience Adverse Events Within 2 Weeks After 3BNC117-LS Infusion in All Study Groups | 2 weeks following the 3BNC117-LS infusion | Adverse events include signs, symptoms and laboratory abnormalities, in addition to local and systemic reactogenicity adverse events. |
| Elimination Half-life (t1/2) of 3BNC117-LS in All Study Groups | 48 weeks | Elimination half-life (t1/2) measured in days of 3BNC117-LS in all study groups |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Frequency of Induced Anti-3BNC117-LS Antibodies in All Study Groups. | 48 weeks | number of participants with induced Anti-3BNC117-LS antibodies in all study groups |
| The Number of Participants Who Experience Adverse Events During Study Follow-up | 48 weeks | Adverse events include signs, symptoms and laboratory abnormalities |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORMarina Caskey, MD
The Rockefeller University
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 2 Participants |
| Age, Continuous | 47 years |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 3 Participants |
| Race (NIH/OMB) More than one race | 2 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 10 Participants |
| Region of Enrollment United States | 2 Participants |
| Sex: Female, Male Female | 4 Participants |
| Sex: Female, Male Male | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 3 | 0 / 3 | 0 / 6 | 0 / 3 | 0 / 6 | 0 / 3 | 0 / 3 | 0 / 6 | 0 / 6 | 0 / 2 | 0 / 2 |
| other Total, other adverse events | 3 / 3 | 2 / 3 | 4 / 6 | 1 / 3 | 4 / 6 | 2 / 3 | 1 / 3 | 3 / 6 | 4 / 6 | 2 / 2 | 1 / 2 |
| serious Total, serious adverse events | 0 / 3 | 0 / 3 | 0 / 6 | 0 / 3 | 0 / 6 | 0 / 3 | 1 / 3 | 0 / 6 | 1 / 6 | 0 / 2 | 0 / 2 |
Outcome results
None listed